ÂÜÀòÂÒÂ×

Bradley Hodges is the founder of Prothelia and currently serves as a scientific advisor to the company. Brad has devoted his 25+ year career to congenital muscular dystrophy, Duchenne, Pompe, FSHD and myotonic dystrophy. Dr. Hodges previously served as Senior Scientist, Genzyme Rare Diseases focused on gene therapies for rare muscle, liver and brain diseases. Following Genzyme, Mr. Hodges served as a rare disease consultant for seed-stage and venture-backed biotechnology companies. Dr. Hodges received his PhD in cell and structural biology from the University of Illinois and has 30+ publications focused on protein and gene therapy approaches for rare diseases.